Please select the eligibility criteria that correspond to the clinical trial below.
Title: DIATOR - Diabetes Intervention With Atorvastatin. A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of Atorvastatin on Residual Beta-cell Function and Glycemic Control in Patients With Newly Diagnosed Type 1 Diabetes Mellitus
Brief Summary: Clinical studies have shown that immunomodulators (like Anti-CD3 antibodies) have effects on beta-cell-preservation. The lipid-lowering agent atorvastatin is also a potent immunomodulator. In this study the effects of 80 mg atorvastatin per day on preservation of beta-cell function in recent onset type 1 diabetes were studied, as determined by stimulated C-peptide levels.


Options:
A: Inclusion Criteria:

* Insulin treated patients with a newly diagnosed type 1 diabetes mellitus as defined by the ADA criteria at least two weeks but not later than 3 months after start of insulin treatment
* Age 18 to 39 years, inclusive
* Male patient or female patient using adequate contraceptive methods
* Tested positive for at least one of the three islet autoantibodies GAD65, IA2 or ICA

Exclusion Criteria:

* History of a malignancy
* Presence of a clinically significant hepatic or renal disease, as indicated, but not limited to a serum creatinine elevated more than ten percent above the upper limit of normal, elevation of AST or ALT more than 3 times the upper limit of normal
* Any other acute or chronic condition that may affect the patient's response to treatment or might be associated with an increased risk for the patient to participate, as judged by the investigator
* Current use of anti-inflammatory or immunomodulatory drugs, antihypertensive, lipid-lowering, or antidiabetic drugs other than insulin
* Pregnant or nursing women or women intending to become pregnant
* Known or suspected allergy to atorvastatin or any component of thr trial product
* Known myopathy, myalgia or myositis with a serum-CPK above 3 times the upper limit of normal
* Patients who had a severe blood loss (\>= 400 mL, e.g. blood donation) within 2 months prior to visit 2
* Any significant laboratory abnormality
* A serum LDL-cholesterol above 150 mg/dL at time of screening
* Unwillingness to comply with study procedures
B: Inclusion Criteria:

* Diabetes mellitus treated with insulin or orl agents
* At least 50 years old

Exclusion Criteria:

* Previous cardiovascular events
* current or past (within last 30 days) treatment with aspirin
* current or past (within last 180 days) treatment with statins
C: Inclusion Criteria:

* \> or = 18 years of age
* Clinical diagnosis-abnormal heart beat known as atrial fibrillation/flutter (ECG documentation)
* Able to swallow pill form of drug

Exclusion Criteria:

* \< 18 years of age
* enrollment in another ongoing trial
* paroxysmal atrial fibrillation
* hemodynamic instability
* atrial fibrillation ablation within 6 months of enrollment
* a contraindication for anticoagulation
* severe valvular heart disease
* presence of single lead implantable cardioverter defibrillator
* unstable angina
* New York Heart Association (NYHA) Class IV heart failure
* hyperthyroidism
* uncontrolled hypertension (blood pressure \> 180/100 at rest) on medications
* an illness that would limit life expectancy to less than 1 year
* use of statins within the previous 30 days
* significant coronary artery disease or lipid abnormalities necessitating statin therapy
* implanted devices for active management of arrhythmias by pacing or defibrillation
* lack of access to a telephone
* illicit drug use
* alcohol abuse
* hypersensitivity to atorvastatin by history
* pregnancy
* sexually active female subjects not on contraception or surgically sterilized
* nursing mothers
* chronic liver disease or abnormal liver function (elevated transaminases 1.5 times the upper limit of normal \[ULN\] of laboratory reference range)
* severe renal disease (creatinine \> 200 mmol/L)
* inflammatory muscle disease or creatine kinase (CK) \> 3 times ULN
* concurrent treatment with cyclosporine, fibrates, or high-dose niacin
D: Inclusion Criteria:

* Men and women between 18 and 80 years of age
* People with abnormal cholesterol levels

Exclusion Criteria:

* People with diabetes
* People whose blood pressure \>160/95 mm Hg, on or off blood pressure medicine
* People who have had frequent chest pain or unstable angina, a heart attack or a heart procedure including stent placement, within the past 3 months

Answer: A